Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) or HEARTLIGHT for the Treatment of Symptomatic Atrial Fibrillation

Location:

Jacksonville, FL., Rochester, MN.
Trial status:
Open for Enrollment
Why is this study being done?

A randomized, controlled trial designed to demonstrate the safety and effectiveness of the experimental device to deliver pulmonary vein isolation as a treatment for symptomatic atrial fibrillation.

Who is eligible to participate?

Inclusion Criteria: - 18 to 75 years. - paroxysmal atrial fibrillation - failure of at least one AAD - others Exclusion Criteria: - overall good health as established by multiple criteria

Last updated:
4/25/2013
NCT ID:
NCT01456000